Product Profiles: Colorectal Cancer - New Drug Combinations and Label Expansions will Increase Competition
NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The colorectal cancer pipeline has grown as pharmaceutical developers are attracted by the unmet need present in this high-incidence cancer type. Cytotoxics remain an integral part of colorectal cancer treatment, but there are a growing number of targeted therapies on the market and in the pipeline. Competition will increase following label expansions and development of new drug combinations. Analysis of marketed colorectal cancer drugs – development history, key clinical trial data, and assessment of clinical and commercial attractiveness. Analysis of marketed drugs in comparison to current standard of care. In-depth analysis of late-stage pipeline drugs – development overview, SWOT analysis, and assessment of clinical and commercial attractiveness. Discussion and assessment of pipeline drugs' ability to meet unmet needs in treatment of colorectal cancer. Eloxatin and Camptosar continue to compete in the metastatic setting through their use in the FOLFOX and FOLFIRI regimens. However, introduction of generic forms has begun to erode branded sales. Xeloda oral formulation has boosted sales in the EU, but has had a negative impact on uptake in the US. Targeted therapies maintain competition for greater market share. Avastin remains dominant, particularly in the US, but Erbitux's label expansion in the EU in 2008 will increase pressure on Avastin in the first-line. Vectibix may finally be able to compete for a larger share of the EU market pending the EMA's final decision. VEGF targeted drugs dominate the late-stage pipeline. Zaltrap is the most advanced drug in the late-stage pipeline and looks set to enter the market in combination with FOLFIRI as a second-line treatment. The development of drugs in combination with existing therapies could increase efficacy and further boost uptake. Understand the dynamics of colorectal cancer therapy and identify the market leaders in this competitive indication. Compare and assess current late-stage pipeline drugs according to market positioning, commercial potential and clinical efficacy. Understand how pipeline drugs will be used with current therapies and how the market is access ed through less competitive treatment settings
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
PRODUCT OVERVIEW
Key marketed and pipeline products
Datamonitor's assessment summary
MARKETED PRODUCT PROFILES
Camptosar (irinotecan; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Eloxatin (oxaliplatin; Sanofi)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Xeloda (capecitabine; Roche/Genentech/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Avastin (bevacizumab; Genentech/Roche/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Vectibix (panitumumab; Amgen)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for colorectal cancer
TS-1 (tegafur, gimeracil, oxonic acid; Taiho)
UFT (tegafur, uracil; Taiho/Merck)
PIPELINE PRODUCT PROFILES
Brivanib (BMS-582664; Bristol-Myers Squibb)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Imprime PGG (Biothera)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
OncoVAX (Intracel/Vaccinogen)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Perifosine (KX-040; AEterna Zentaris/Keryx Biopharmaceuticals)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Ramucirumab (Eli Lilly)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Regorafenib (Bayer)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Zaltrap (aflibercept/VEGF-Trap; Regeneron/Sanofi)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Market definition
PharmaVitae Explorer database
Contributing experts
Report methodology
TABLES
Table: Key marketed and pipeline products for colorectal cancer, 2011
Table: Camptosar – drug profile, 2011
Table: Overview of major colorectal cancer approvals for Camptosar
Table: Overview of pivotal trial data for Camptosar in colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Camptosar for colorectal cancer, 2011
Table: Eloxatin – drug profile, 2011
Table: Overview of major colorectal cancer approvals for Eloxatin
Table: Overview of pivotal trial data for Eloxatin in colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Eloxatin for colorectal cancer, 2011
Table: Xeloda – drug profile, 2011
Table: Overview of major colorectal cancer approvals for Xeloda
Table: Overview of pivotal trial data for Xeloda in colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Xeloda for colorectal cancer, 2011
Table: Avastin – drug profile, 2011
Table: Overview of major CRC approvals for Avastin
Table: Overview of pivotal trial data for Avastin in colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Avastin for colorectal cancer, 2011
Table: Erbitux – drug profile, 2011
Table: Overview of major colorectal cancer approvals for Erbitux
Table: Overview of pivotal trial data for Eloxatin in colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Erbitux for colorectal cancer, 2011
Table: Vectibix – drug profile, 2011
Table: Overview of major CRC approvals for Vectibix
Table: Overview of pivotal trial data for Vectibix in colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Vectibix for colorectal cancer, 2011
Table: TS-1 – drug profile, 2011
Table: UFT – drug profile, 2011
Table: Brivanib – drug profile, 2011
Table: Clinical development of brivanib, 2011
Table: Ability of brivanib to meet unmet needs in second-line colorectal cancer, 2011
Table: Datamonitor drug assessment summary of brivanib for colorectal cancer, 2011
Table: Imprime PGG – drug profile, 2011
Table: Clinical development of Imprime PGG, 2011
Table: Ability of Imprime PGG to meet unmet needs in second-line colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Imprime PGG for colorectal cancer, 2011
Table: OncoVAX – drug profile, 2011
Table: Clinical development of OncoVAX, 2011
Table: Ability of OncoVAX to meet unmet needs in adjuvant colorectal cancer, 2010
Table: Datamonitor drug assessment summary of OncoVAX for colorectal cancer, 2011
Table: Perifosine – drug profile, 2011
Table: Clinical development of perifosine, 2011
Table: Ability of perifosine to meet unmet needs in second-line colorectal cancer, 2011
Table: Datamonitor drug assessment summary of perifosine for colorectal cancer, 2011
Table: Ramucirumab – drug profile, 2011
Table: Clinical development of ramucirumab, 2011
Table: Summary of Phase I clinical trial data for ramucirumab in solid tumors
Table: Datamonitor drug assessment summary of ramucirumab for colorectal cancer, 2011
Table: Regorafenib – drug profile, 2011
Table: Clinical development of regorafenib, 2011
Table: Summary of Phase I clinical trial data for regorafenib in advanced refractory colorectal cancer
Table: Datamonitor drug assessment summary of regorafenib for colorectal cancer, 2011
Table: Zaltrap – drug profile, 2011
Table: Clinical development of Zaltrap, 2011
Table: Ability of Zaltrap to meet unmet needs in second-line colorectal cancer, 2011
Table: Datamonitor drug assessment summary of Zaltrap for colorectal cancer, 2011
Table: Summary of therapeutic classes in colorectal cancer by ATC code, 2011
FIGURES
Figure: Datamonitor's drug assessment summary of key marketed drugs for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of pipeline drugs for metastatic colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of pipeline drugs for early-stage colorectal cancer, 2011
Figure: Camptosar's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Camptosar for colorectal cancer, 2011
Figure: Eloxatin's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Eloxatin for colorectal cancer, 2011
Figure: Xeloda's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Xeloda for colorectal cancer, 2011
Figure: Avastin's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Avastin for colorectal cancer, 2011
Figure: Erbitux's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Erbitux for colorectal cancer, 2011
Figure: Vectibix's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Vectibix for colorectal cancer, 2011
Figure: Phase I/II results for second-line brivanib and Erbitux in metastatic colorectal cancer
Figure: Brivanib's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of brivanib for metastatic colorectal cancer, 2011
Figure: Phase Ib/IIa results for Imprime in combination with Erbitux with or without irinotecan in metastatic colorectal cancer
Figure: Imprime PGG's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Imprime PGG for metastatic colorectal cancer, 2011
Figure: Phase IIIa results for adjuvant OncoVAX in Stage II and III colorectal cancer
Figure: OncoVAX's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of OncoVAX for colorectal cancer, 2011
Figure: Phase II results for second-/third-line perifosine and Xeloda in metastatic colorectal cancer
Figure: Perifosine's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of perifosine for metastatic colorectal cancer, 2011
Figure: Ramucirumab's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of ramucirumab for metastatic colorectal cancer, 2011
Figure: Regorafenib's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of regorafenib for metastatic colorectal cancer, 2011
Figure: Phase II results for second-line Zaltrap monotherapy in metastatic colorectal cancer
Figure: Zaltrap's SWOT analysis for colorectal cancer, 2011
Figure: Datamonitor's drug assessment summary of Zaltrap for metastatic colorectal cancer, 2011
Figure: The PharmaVitae Explorer
Companies Mentioned
Anheuser-Busch InBev SA/NV, Brossard SA, Chattem, Inc., Hutchison 3G UK Limited, Merck KGaA, Omnicom Group Inc., Puig, Schindler Holding Ltd.
To order this report:
Pathology Industry: Product Profiles: Colorectal Cancer – New drug combinations and label expansions will increase competition
Pathology Business News
Check our Industry Analysis and Insights
Contact: Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article